A crucial role of MafA as a novel therapeutic target for diabetes

J Biol Chem. 2005 Apr 15;280(15):15047-52. doi: 10.1074/jbc.M412013200. Epub 2005 Jan 20.

Abstract

MafA, a recently isolated pancreatic beta-cell-specific transcription factor, is a potent activator of insulin gene transcription. In this study, we show that MafA overexpression, together with PDX-1 (pancreatic and duodenal homeobox factor-1) and NeuroD, markedly increases insulin gene expression in the liver. Consequently, substantial amounts of insulin protein were induced by such combination. Furthermore, in streptozotocin-induced diabetic mice, MafA overexpression in the liver, together with PDX-1 and NeuroD, dramatically ameliorated glucose tolerance, while combination of PDX-1 and NeuroD was much less effective. These results suggest a crucial role of MafA as a novel therapeutic target for diabetes.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenoviridae / genetics
  • Animals
  • Basic Helix-Loop-Helix Transcription Factors
  • Blotting, Northern
  • Cell Line
  • DNA-Binding Proteins / biosynthesis
  • Diabetes Mellitus / therapy*
  • Diabetes Mellitus, Experimental
  • Glucose / metabolism
  • Homeodomain Proteins / biosynthesis
  • Humans
  • Immunohistochemistry
  • Insulin / metabolism
  • Liver / metabolism
  • Luciferases / metabolism
  • Maf Transcription Factors, Large
  • Male
  • Mice
  • Mice, Inbred C57BL
  • Streptozocin / pharmacology
  • Time Factors
  • Trans-Activators / biosynthesis
  • Trans-Activators / metabolism
  • Trans-Activators / physiology*
  • Transfection

Substances

  • Basic Helix-Loop-Helix Transcription Factors
  • DNA-Binding Proteins
  • Homeodomain Proteins
  • Insulin
  • MAFA protein, human
  • Maf Transcription Factors, Large
  • NEUROD1 protein, human
  • Neurod1 protein, mouse
  • Trans-Activators
  • pancreatic and duodenal homeobox 1 protein
  • Streptozocin
  • Luciferases
  • Glucose